Logo image of OMER

OMEROS CORP (OMER) Stock Fundamental Analysis

NASDAQ:OMER - Nasdaq - US6821431029 - Common Stock - Currency: USD

3.61  -0.32 (-8.14%)

After market: 3.62 +0.01 (+0.28%)

Fundamental Rating

1

Overall OMER gets a fundamental rating of 1 out of 10. We evaluated OMER against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of OMER have multiple concerns. OMER has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OMER had negative earnings in the past year.
In the past year OMER has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: OMER reported negative net income in multiple years.
In the past 5 years OMER reported 4 times negative operating cash flow.
OMER Yearly Net Income VS EBIT VS OCF VS FCFOMER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -65.08%, OMER is doing worse than 66.32% of the companies in the same industry.
Industry RankSector Rank
ROA -65.08%
ROE N/A
ROIC N/A
ROA(3y)-26.61%
ROA(5y)-21.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OMER Yearly ROA, ROE, ROICOMER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

OMER does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMER Yearly Profit, Operating, Gross MarginsOMER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

1

2. Health

2.1 Basic Checks

OMER has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, OMER has more shares outstanding
The debt/assets ratio for OMER is higher compared to a year ago.
OMER Yearly Shares OutstandingOMER Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OMER Yearly Total Debt VS Total AssetsOMER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -7.56, we must say that OMER is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.56, OMER is not doing good in the industry: 66.84% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.56
ROIC/WACCN/A
WACCN/A
OMER Yearly LT Debt VS Equity VS FCFOMER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 1.16 indicates that OMER should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.16, OMER is doing worse than 80.31% of the companies in the same industry.
OMER has a Quick Ratio of 1.16. This is a normal value and indicates that OMER is financially healthy and should not expect problems in meeting its short term obligations.
OMER has a worse Quick ratio (1.16) than 71.50% of its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.16
OMER Yearly Current Assets VS Current LiabilitesOMER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

OMER shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -34.52%.
EPS 1Y (TTM)-34.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, OMER will show a very strong growth in Earnings Per Share. The EPS will grow by 27.96% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.67%
EPS Next 2Y39.74%
EPS Next 3Y28.18%
EPS Next 5Y27.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OMER Yearly Revenue VS EstimatesOMER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
OMER Yearly EPS VS EstimatesOMER Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OMER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OMER is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OMER Price Earnings VS Forward Price EarningsOMER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMER Per share dataOMER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

OMER's earnings are expected to grow with 28.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.74%
EPS Next 3Y28.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OMER!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OMEROS CORP

NASDAQ:OMER (7/15/2025, 8:11:58 PM)

After market: 3.62 +0.01 (+0.28%)

3.61

-0.32 (-8.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-06 2025-08-06
Inst Owners47.43%
Inst Owner Change0%
Ins Owners4.37%
Ins Owner Change0%
Market Cap211.51M
Analysts80
Price Target30.6 (747.65%)
Short Float %24.14%
Short Ratio12.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.78%
Min EPS beat(2)-0.35%
Max EPS beat(2)31.91%
EPS beat(4)3
Avg EPS beat(4)17.46%
Min EPS beat(4)-0.35%
Max EPS beat(4)31.91%
EPS beat(8)5
Avg EPS beat(8)17.46%
EPS beat(12)9
Avg EPS beat(12)56.44%
EPS beat(16)12
Avg EPS beat(16)47.19%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-25.93%
PT rev (3m)-25.93%
EPS NQ rev (1m)2.33%
EPS NQ rev (3m)9.61%
EPS NY rev (1m)11.09%
EPS NY rev (3m)6.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-25%
Revenue NY rev (1m)30%
Revenue NY rev (3m)-45.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.65
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-2.44
FCFYN/A
OCF(TTM)-2.43
OCFYN/A
SpS0
BVpS-3.64
TBVpS-3.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.08%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.61%
ROA(5y)-21.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.05%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 1.16
Altman-Z -7.56
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)25.18%
Cap/Depr(5y)22.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.94%
EPS Next Y27.67%
EPS Next 2Y39.74%
EPS Next 3Y28.18%
EPS Next 5Y27.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-238.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-238.15%
OCF growth 3YN/A
OCF growth 5YN/A